TAC1 and cystic fibrosis: Most of the described mutations result in drug resistance and are selected for during antifungal therapy of patients with Candida infections (GOF mutations in Tac1, Mrr1, and Upc2), but they can also increase fitness in certain host niches, such as the CF lung in which fungal cells have to compete with antagonistic bacteria (Rob1, Mrr1).